Femasys announced that it has it has received notice from The Nasdaq Stock Market LLC informing Femasys that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 555 for continued listing on The Nasdaq Capital Market. Consequently, Femasys is now in compliance with all applicable listing standards, and its common stock will continue to be listed on The Nasdaq Capital Market.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on FEMY:
- Femasys Inc. Regains Compliance with Nasdaq Listing Requirements
- Femasys Inc. to Showcase FemaSeed at the Annual Meeting of the American Society of Reproductive Medicine
- Femasys announces completion of MDSAP surveillance audit
- Femasys Inc. MDSAP Surveillance Audit Successfully Completed
- Femasys price target raised to $13 from $5 at H.C. Wainwright